152 related articles for article (PubMed ID: 10875608)
1. Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Van Laethem K; Schmit JC; Pelemans H; Balzarini J; Witvrouw M; Pérez-Pérez MJ; Camarasa MJ; Esnouf RM; Aquaro S; Cenci A; Perno CF; Hermans P; Sprecher S; Ruiz L; Clotet B; Van Wijngaerden E; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
AIDS Res Hum Retroviruses; 2000 Jun; 16(9):825-33. PubMed ID: 10875608
[TBL] [Abstract][Full Text] [Related]
2. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
Balzarini J; Velazquez S; San-Felix A; Karlsson A; Perez-Perez MJ; Camarasa MJ; De Clercq E
Mol Pharmacol; 1993 Jan; 43(1):109-14. PubMed ID: 7678689
[TBL] [Abstract][Full Text] [Related]
4. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
de Castro S; García-Aparicio C; Van Laethem K; Gago F; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Antiviral Res; 2006 Aug; 71(1):15-23. PubMed ID: 16616962
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
7. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
9. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
[TBL] [Abstract][Full Text] [Related]
10. "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains.
Lobatón E; Velázquez S; Pérez-Pérez MJ; Jimeno ML; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):707-10. PubMed ID: 11563097
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
[TBL] [Abstract][Full Text] [Related]
12. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
[TBL] [Abstract][Full Text] [Related]
13. 4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family.
Lobatón E; Velázquez S; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):711-4. PubMed ID: 11563098
[TBL] [Abstract][Full Text] [Related]
14. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).
Balzarini J; Pérez-Pérez MJ; Vélazquez S; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5470-4. PubMed ID: 7539917
[TBL] [Abstract][Full Text] [Related]
16. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
[TBL] [Abstract][Full Text] [Related]
17. 1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
Alvarez R; Velázquez S; San-Félix A; Aquaro S; De Clercq E; Perno CF; Karlsson A; Balzarini J; Camarasa MJ
J Med Chem; 1994 Nov; 37(24):4185-94. PubMed ID: 7527463
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
19. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
20. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
